Trial NCT05261490

View at ClinicalTrials.gov 
Org. Study IDs: TTI-622-02
Secondary IDs: C4971002

Last trial update was posted on 2024-04-05

MeSH Interventions

Doxorubicin Liposomal doxorubicin

MeSH Conditions

Carcinoma Carcinoma, Ovarian Epithelial Fallopian Tube Neoplasms Ovarian Neoplasms

Other Conditions

Epithelial Ovarian Cancer Fallopian Tube Cancer Ovarian Cancer Ovarian Carcinoma Primary Peritoneal Carcinoma

Stopping Reasons

A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID